What it sells
Curative genetic medicines for kidney diseases
Business model breakdown
Workflow: what inputs become what output?
NeFIND platform combines AI and high-throughput in vivo screening to design AAV delivery vehicles with kidney and pancreas tropism, claimed 10-100x more efficient.
Economics: what it saves and how it charges
Preclinical biotech (Stanford spinout) developing its own genetic medicines; no revenue model published.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2020 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.